New agents in medical oncology and the risk of venous thromboembolism

Journal of Experimental and Clinical Cancer Research

Volumn 26, Issue 2, 2007, Pages 185-194

  Manzoni, M ^a   Bencardino, K ^a   Piovella, F ^a   Chatzileontiadou, S ^a   Delfanti, S ^a   Riccardi, A ^a   Danova, Marco ^a   Corazza, G R ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Chemotherapy; New drugs; Thromboembolism; Toxicity

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ACETYLSALICYLIC ACID; ANASTROZOLE; ANGIOGENESIS INHIBITOR; AROMATASE INHIBITOR; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HEPARIN; IMC 1121; IRINOTECAN; LETROZOLE; PACLITAXEL; PLACEBO; RECOMBINANT ERYTHROPOIETIN; SEMAXANIB; TAMOXIFEN; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; WARFARIN;

ANEMIA; BLEEDING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; FOLLOW UP; HEAD AND NECK CANCER; HORMONAL THERAPY; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MULTIPLE MYELOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; STOMACH CANCER; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS; TREATMENT RESPONSE; TUMOR GROWTH; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; RISK; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 34347380864     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Loreto M.F., De Martinis M., Corsi M.P. et al: Coagulation and cancer: implications for diagnosis and management. Pathol. Oncol. Res. 6 (4): 301-312, 2000.
2. De Cicco M.: The prothrombotic state in cancer: pathogenic mechanisms. Crit. Rew. One. Hemat. 56: 187-196, 2004.
3. Barbui T. and Falanga A.: Thalidomide and thrombosis in multiple myeloma. J. Thromb. Haemost. 1: 421-422, 2003.
4. Rajkumar S.V.: Thalidomide therapy and deep venous thrombosis in multiple myeloma. Mayo Clin. Proc. 80 (12): 1549-1551, 2005.
5. Barlogie B., Desikan R., Eddlemon P. et al: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 98: 492-494, 2001.
6. Osman K., Comenzo R., Rajkumar S.V.: Deep venous thrombosis and thalidomide therapy for multiple myeloma. New Eng. J. Med. 344: 1951-1952, 2001.
7. Urbauer E., Kaufmann H., Nosslinger T. et al: Thromboembolic events during treatment with thalidomide. Blood 99: 4247-4248, 2002.
8. Zangari M., Anaissie E., Barlogie B. et al: Increased risk of deep vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98: 1641-1645, 2001
9. Barlogie B., Tricot G., Anaissie E. et al: Thalidomide and hematopoietic-cell transplation for multiple myeloma. New Engl. J. Med. 354:1021-1030, 2006.
10. Zangari M., Siegel E., Barlogie B. et al: Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 100: 1168-1171, 2002.
11. Zangari M., Barlogie B., Cavallo F. et al: Effect on survival of treatment associated deep vein thrombosis in newly diagnosed multiple myeoloma patients. Proc. Am. Soc. Clin. Oncol. 2006 abs 3019.
12. Zangari M., Barlogie B., Thertulien R. et al: Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin. Lymphoma 4 (1): 32-35, 2003.
13. Zangari M., Saghafifar F., Anaissie A. et al: Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul. Fibrinolysis 13(3): 187-192,2002.
14. Hugo J.Z. and Jeanet D.M..: Acquired activated protein C resistence and thrombosis in multiple myeloma patients. Throm. J. 4(11), 2006.
15. Minnema M.C., Fijnheer R., De Groot P.G. et al: Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J. Thromb. Haemost. 1: 445-449, 2003.
16. Escudier B., Lassau N., Couanet D. et al: Phase II trial of thalidomide in renal-cell carcinoma. Ann. Oncol. 117: 508-515, 2004.
17. Kaushal V., Kaushal G.P., Melkaveri S.N. et al: Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. J. Thromb. Haemost. 2 (2): 327-334, 2004.
18. Zangari M., Barlogie B., Anaissie E. et al: Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br. J. Haematol. 126 (5): 715-721, 2004.
19. Ikhlaque N., Seshadri V., Kathula S. et al.: Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. Am. J. Hematol. 81(6): 420-422, 2006.
20. Miller C., Padmanabhan S., Dimicelli L. et al: Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. Leuk. Lymph. 47 (11): 2339-2343, 2006.
21. Baz R., Li L., Kottke-Marchant K. et al: The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin. Proc.80(12): 1568-1574, 2005.
22. Kabbinavar F., Hurwitz H., Fehrenbacher L. et al: Phase II, randomized trial comparing bevacizumab plus Fluouracil (FU)/Leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. JCO 21 (1): 60-65, 2003.
23. Shah M., Ilson D., Kelsen D.: Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. JCO 23 (11): 2574-2576, 2003.
24. Langmuir V., Cobleigh M., Herbst R. et al: Successful long-term therapy with Bevacizumab (Avastin) in solid tumours. Proc. Am. Soc. Clin. Oncol. 2002 abs 32.
25. Hurwitz H., Fehrenbacher L., Novotny W. et al: Bevacizumab plus Irinotecan, Fluorouracil and Leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 305 (23): 2335-2342, 2004.
26. Kabbinavar F., Schulz J., McCleod M. et al: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. JCO 23 (16): 3697-3705, 2005.
27. Hochster H.S., Welles L., Hart L. et al: Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1&2 studies. Proc. Am. Soc. Clin. Oncol. 2005 abs 3515.
28. Gianantonio B.J., Catalano P.J., Meropol N.J. et al: High-dose bevacizumab improves survival when combined with FOL-FOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc. Am. Soc. Clin. Oncol. 2005 abs 2.
29. Miller K.D., Chap L.I., Holmes F.A. et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. JCO 23 (4): 792-799, 2005.
30. Lyons J.A., Silverman P., Remick S. et al: Toxicity resukts and early outcome data on a randomized phase II study of docetaxel +/- Bevacizumab for locally advanced unresectable breast cancer. Proc. Am. Soc. Clin. One. 2006 abs 3049.
31. Novotny W.F., Holmgren E., Nelson B. et al: Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) does not increase the incidence of venous thromboembolism when added to first-line chemotherapy to treat metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 2004 abs 3529.
32. Skillings J.R., Johnson D.H., Miller K. et al: Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. Proc. Am. Soc. Clin. Oncol. 2005 abs 3019.
33. Fyfe G.A., Hurwitz H., Fehrenbacher L. et al: Bevacizumab plus irinotecan/5FU/ leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patients subgroups. Proc. Am. Soc. Clin. Oncol. 2004 abs 3617.
34. Hedrick E., Kozloff M., Hainsworth J. et al: Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: update results from a large observational registry in the US (BRITE). Proc. Am. Soc. Clin. Oncol. 2006 abs 3536.
35. Berry S.R., Cunningham D., Michel M. et al: Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and Capecitabine for mCRC- First B.E.A. trial. Proc. Am. Soc. Clin. Oncol. 2006 abs 3534.
36. Hambleton J., Novotny W.F., Hurwitz H. et al: Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. Proc. Am. Soc. Clin. Oncol. 2004 abs 3528.
37. Hambleton J., Skillings J., Kabbinavar F. et al: Safety of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). Proc. Am. Soc. Clin. Oncol. 2005 abs 3554.
38. Gordon M.S., Cunningham D.: Managing patients treated with bevacizumab combination therapy. Oncology 69 (3): 25-33, 2005.
39. Fong T.A., Shawver L.K., Sun L. et al: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumour vascularisation, and growth of multiple tumour types. Cancer Res. 59: 99-106, 1999.
40. Mendel D.B., Laird A.D., Smolich B.D. et al: Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des. 15 (1): 29-41, 2000.
41. Kuenen B., Rosen L., Smit E.F. et al: Dose-finding and pharmacokinetic study of cisplatin, gemcitabine and SU5416 in patients with solid tumors. JCO 20 (6): 1657-1667, 2002.
42. Kuenen B., Tabernero J., Baselga J. et al: Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin. Cancer Res. 9: 16481655, 2003.
43. Kuenen B., Levi M., Meijers J.C.M. et al: Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine and the angiogenesis inhibitor SU5416. JCO 21 (11): 2192-2198, 2003.
44. Rosen P., Kabbinavar F., Figlin R. et al: A phase I/II trial and pharmacokinetic study of SU5416 in combination with paclitaxel/carboplatin. Proc. Am. Soc. Clin. Oncol. 2001 abs 389
45. Ma L., Francia G., Viloria-Petit A. et al: In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenetic drug combinations: modulation by lower-dose chemotherapy. Cancer Res. 65 (12): 5365-5373, 2005.
46. Rosen P., Amado R., Hecht J. et al: A phase I/II study of SU5416 in combination with 5-FU/Leucovorin in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 2000 abs 5D.
47. Gradishar W.J.: Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women. Oncology 69: 1-9, 2005.
48. Deitcher S.R .and Gomes M.P.: The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma. Cancer 101 (3): 439-449, 2004.
49. Cosman F., Baz-Hecht M., Cushman M. et al: Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literarature. Thromb. Res. 116(1): 1-13, 2005.
50. Baum M., Buzdar A., Cuzick J., The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98 (9): 1802-1810, 2003.
51. Distler W., on behalf of the ATAC Trialists' Group: Safety and efficacy data from the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial after completation of 5 years' adjuvanr treatment. Breast 14 (1) P128, 2005.
52. Thurlimann B., Keshaviah A., Coates A.S. et al: A comparison of letrozole and Tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 29; 353 (26): 2747-2757, 2005
53. Monier A.: The evolving role of letrozole in the adjuvant. setting: first results from the large, phase III, randomized trial BIG 1-98. Breast 15: 21-29, 2006.
54. Coombes R.C., Hall E., Gibson L.J. et al: A randomized trial of examestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350: 1081-1092, 2004.
55. Kaufmann M., Jakesz R., Gnant M. et al: On behalf of the GABG and the ABCSG. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrazole after 2 years adjuvant tamoxifen: combined results from 3123 patients enrolled in the ABCSG trial 8 and the ARNO 95 trial. Breast 14 (1), Abs P81, 2005.
56. Goss P.E., Ingle J.N., Martino S. et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med 349: 1793-1802, 2003.
57. Goss P.E., Ingle J.N., Martino S. et al: Update analysis of the NCIC CTG MA17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. Proc. Am. Soc. Clin. Oncol. 2004 abs 847.
58. Nabholtz J.M., Buzdar A., Pollak M. et al: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. JCO 18 (22): 3758-3767, 2000.
59. Bonneterre J., Thurlimann B., Robertson J.F.R. et al: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. JCO 18 (22): 3748-3757, 2000.
60. Nabholtz J.M., Bonneterre J., Budzar A. et al: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur. J. Cancer 39: 1684-1689, 2003.
61. Mouridsen H., Gershanovich M., Sun Y. et al: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from International Letrozole Breast Cancer group. JCO 21 (11): 2101-2109, 2003.
62. Engert A.: Recombinant human erythropoietin in oncology: current status and further developments. Ann. Oncol. 16 (10): 1584-1595, 2005.
63. Bokemeyer C., Aapro M.S., Courdi A. et al: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur. J. Cancer 40: 2201-2216, 2004.
64. Henke M., Laszing R., Rube C. et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo controlled trial. Lancet 18 (362): 1255-1260, 2003.
65. Leyland-Jones B., on behalf of the BEST Investigators and Study Group: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4(8): 459-460, 2003.
66. Bohlius J., Langensiepen S., Schwarzer G. et al: Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J. Natl. Cancer Inst. 97: 489-498, 2005.
67. Bohlius J., Wilson J., Seidenfeld J. et al: Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J. Natl. Cancer Inst. 98 (10): 708-714, 2006.
68. Barbui T., Finazzi G., Grassi A. et al: Thrombosis in cancer patients treated with hematopoietic grouth-factors: a meta-analysis. Thromb. Haemost. 75: 368-371, 1996.
69. Falanga A., Marchetti M., Evangelista V. et al: Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood 93 (8): 2506-2514, 1999.
70. Guba M., Yezhelyev M., Eichhom M.E. et al: Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood 105 (11): 4463-69, 2005.
71. Rak J, Milsom C, May L, Klement P et al: Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularisation and cancer coagulopathy. Semin. Thromb. Hemost. 32 (1): 54-70, 2006.